Literature DB >> 27405129

DIAGNOSTIC TEST OF SPUTUM GENEXPERT MTB/RIF FOR SMEAR NEGATIVE PULMONARY TUBERCULOSIS.

Wipa Reechaipichitkul, Attawoot Phetsuriyawong, Prajuab Chaimanee, Pimjai Ananta.   

Abstract

The objective of this study was to evaluate the performance of the Gene-Xpert MTB/RIF sputum test for diagnosing pulmonary tuberculosis (TB) among patients sputum acid-fast bacillus (AFB) smear negative results in Thailand, a country with a high prevalence of pulmonary tuberculosis. We studied 151 patients who presented to Srinagarind Hospital, Khon Kaen, Thailand with a 2 week or more history of fever and/or cough and an abnormal chest radiograph between 2010 and 2014; these patients had at least 2 negative sputum AFB smear results. Of these, 76 were diagnosed as having either confirmed or probable pulmonary TB: the 32 confirmed cases were those with a positive sputum culture for Mycobacterium tuberculosis (MTB) and the 44 probable case were those with clinical and radiographic findings consistent with TB and who had a response to anti-TB therapy. Seventy-five cases were diagnosed as not having pulmonary TB. Of the 32 patients with a positive sputum culture for MTB, 26 had a positive GeneXpert MTB/RIF sputum test. Compared to sputum culture for MTB the GeneXpert MTB/ RIF test gave a sensitivity of 83.9% (95% CI: 66.3-94.5) and a specificity of 92.1% (95% CI: 83.6-97), a positive predictive value (PPV) of 81.3% (95% CI: 63.6-92.8) and a negative predictive value (NPV) of 93.3% (95% CI: 85.1-97.8). The GeneXpert MTB/RIF test had a fair sensitivity and specificity for diagnosing smear negative pulmonary TB. It may be useful for diagnosing pulmonary TB in patients with a negative sputum AFB smear. The assay is faster than culture and can detect rifampicin resistant strains of MTB.

Entities:  

Mesh:

Year:  2016        PMID: 27405129

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  4 in total

1.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

2.  Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settings.

Authors:  Nila J Dharan; Robert Blakemore; Alex Sloutsky; Devinder Kaur; Richard C Alexander; Minoo Ghajar; Kimberlee A Musser; Vincent E Escuyer; Marie-Claire Rowlinson; Susanne Crowe; Rafael Laniado-Laborin; Eloise Valli; Pamela Nabeta; Pamela Johnson; David Alland
Journal:  BMC Infect Dis       Date:  2016-12-20       Impact factor: 3.090

3.  Tuberculosis Chemotherapy Outcome in the Littoral Region of Cameroon: A Meta-analysis of Treatment Success Rate between 2014 and 2016.

Authors:  Dorgelesse F Kouemo Motse; Dickson Shey Nsagha; Dieudonné Adiogo; Loick P Kojom Foko; Pride M Teyim; Alain Chichom-Mefire; Jules C Nguedia Assob
Journal:  Biomed Res Int       Date:  2020-07-08       Impact factor: 3.411

4.  Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF.

Authors:  Giulia Lombardi; Valentina Di Gregori; Nicolò Girometti; Marina Tadolini; Francesco Bisognin; Paola Dal Monte
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.